Jaguar Health, Inc. (JAGX): R&D Expense
$24.97M
Year ended 2025-12-31
$25.23M
Trailing 12 months to 2026-06-30
+12.3%
3-year compound annual growth
+31.2%
5-year compound annual growth
+14.4%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.97M | +50.9% | 2026-04-07, From 2025-01-01 |
| 2024-12-31 | $16.54M | -11.0% | 2026-04-07, From 2024-01-01 |
| 2023-12-31 | $18.60M | +5.4% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $17.65M | +17.0% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $15.08M | +135.1% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $6.41M | +10.2% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $5.82M | +12.9% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $5.15M | +20.7% | 2020-04-03, From 2018-01-01 |
| 2017-12-31 | $4.27M | -40.8% | 2019-04-10, From 2017-01-01 |
| 2016-12-31 | $7.21M | +11.3% | 2018-04-09, From 2016-01-01 |
| 2015-12-31 | $6.48M | +53.4% | 2017-02-15, From 2015-01-01 |
| 2014-12-31 | $4.22M | n/a | 2016-03-29, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $24.97M | +50.9% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $94.30M | -20.1% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $138.09M | +868.4% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $313.0K | -52.4% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $74.04M | +15.3% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $44.49M | +11.3% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $125.90M | +84.1% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $168.06M | +20.8% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $41.33M | -22.1% |
Compare JAGX, PRLD, CBIO, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗